Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kauko, Otto ^a,b   Laajala, Teemu Daniel ^b,c   Jumppanen, Mikael ^a   Hintsanen, Petteri ^d   Suni, Veronika ^a,e   Haapaniemi, Pekka ^a   Corthals, Garry ^a,f   Aittokallio, Tero ^d   Westermarck, Jukka ^a,b   Imanishi, Susumu Y ^a,g  

^a TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Drug Research Doctoral Programme (DRDP)   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e TURKU CENTRE FOR COMPUTER SCIENCE   (Finland)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g MEIJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHOSPHOPEPTIDE; PHOSPHOPROTEIN PHOSPHATASE 2; RAS PROTEIN; SMALL INTERFERING RNA; TITANIUM; TITANIUM DIOXIDE;

ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; CELL PROLIFERATION; CHEMISTRY; CLUSTER ANALYSIS; GENETICS; HELA CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

AREA UNDER CURVE; AUTOANTIGENS; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLUSTER ANALYSIS; HELA CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MEMBRANE PROTEINS; NEOPLASMS; PHOSPHOPEPTIDES; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; ROC CURVE; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TITANIUM;

EID: 84939558729     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13099     Document Type: Article

References (75)

1. Brognard, J. & Hunter, T. Protein kinase signaling networks in cancer. Curr Opin Genet Dev 21, 4-11 (2011).
2. Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9, 28-39 (2009).
3. Rajalingam, K., Schreck, R., Rapp, U. R. & Albert, S. Ras oncogenes and their downstream targets. Biochim Biophys Acta 1773, 1177-1195 (2007).
4. Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res 72, 2457-2467 (2012).
5. Haluska, F. G. et al. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12, 2301s-2307s (2006).
6. Hunter, T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80, 225-236 (1995).
7. Sablina, A. A. & Hahn, W. C. SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev 27, 137-146 (2008).
8. Eichhorn, P. J., Creyghton, M. P. & Bernards, R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 1795, 1-15 (2009).
9. Westermarck, J. & Hahn, W. C. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 14, 152-160 (2008).
10. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 45, 1134-1140 (2013).
11. Chen, J., Martin, B. L. & Brautigan, D. L. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257, 1261-1264 (1992).
12. Junttila, M. R. et al. CIP2A inhibits PP2A in human malignancies. Cell 130, 51-62 (2007).
13. Laine, A. et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 3, 182-197 (2013).
14. Hahn, W. C. et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 22, 2111-2123 (2002).
15. Rangarajan, A., Hong, S. J., Gifford, A. & Weinberg, R. A. Species-and cell type-specific requirements for cellular transformation. Cancer Cell 6, 171-183 (2004).
16. Sablina, A. A., Hector, M., Colpaert, N. & Hahn, W. C. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 70, 10474-10484 (2010).
17. Zhao, J. J. et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3, 483-495 (2003).
18. Naetar, N. et al. PP2A-Mediated Regulation of Ras Signaling in G2 Is Essential for Stable Quiescence and Normal G1 Length. Mol Cell 54, 932-945 (2014).
19. Mathiasen, D. P. et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 31, 390-401 (2012).
20. Olsen, J. V. et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648 (2006).
21. Jensen, O. N. Interpreting the protein language using proteomics. Nat Rev Mol Cell Biol 7, 391-403 (2006).
22. Larsen, M. R., Thingholm, T. E., Jensen, O. N., Roepstorff, P. & Jorgensen, T. J. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics 4, 873-886 (2005).
23. Zhang, Y., Fonslow, B. R., Shan, B., Baek, M. C. & Yates, J. R., 3rd Protein analysis by shotgun/bottom-up proteomics. Chem Rev 113, 2343-2394 (2013).
24. Engholm-Keller, K. & Larsen, M. R. Technologies and challenges in large-scale phosphoproteomics. Proteomics 13, 910-931 (2013).
25. Sharma, K. et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of tyr and ser/thr-based signaling. Cell Rep 8, 1583-1594 (2014).
26. Imanishi, S. Y. et al. Reference-facilitated phosphoproteomics: fast and reliable phosphopeptide validation by microLC-ESI-QTOF MS/MS. Mol Cell Proteomics 6, 1380-1391 (2007).
27. Ohman, T. et al. Phosphoproteomics Combined with Quantitative 14-3-3-affinity Capture Identifies SIRT1 and RAI as Novel Regulators of Cytosolic Double-stranded RNA Recognition Pathway. Mol Cell Proteomics 13, 2604-2617 (2014).
28. Ong, S. E. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1, 376-386 (2002).
29. Ross, P. L. et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3, 1154-1169 (2004).
30. Wang, Y. T. et al. An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-5597 (2010).
31. Soderblom, E. J., Philipp, M., Thompson, J. W., Caron, M. G. & Moseley, M. A. Quantitative Label-Free Phosphoproteomics Strategy for Multifaceted Experimental Designs. Anal Chem 83, 3758-3764 (2011).
32. Yang, F. et al. Applying a targeted label-free approach using LC-MS AMT tags to evaluate changes in protein phosphorylation following phosphatase inhibition. J Proteome Res 6, 4489-4497 (2007).
33. Montoya, A., Beltran, L., Casado, P., Rodriguez-Prados, J. C. & Cutillas, P. R. Characterization of a TiO(2) enrichment method for label-free quantitative phosphoproteomics. Methods 54, 370-378 (2011).
34. de Graaf, E. L., Giansanti, P., Altelaar, A. F. & Heck, A. J. Single step enrichment by Ti4 +-IMAC and label free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution. Mol Cell Proteomics 13, 2426-2434 (2014).
35. Manes, N. P. et al. Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927 (2011).
36. Lundby, A. et al. Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 (2012).
37. Casado, P. et al. Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci Signal 6, rs6 (2013).
38. Gnad, F. et al. Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics. Mol Cell Proteomics 12, 2070-2080 (2013).
39. Dephoure, N. et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA 105, 10762-10767 (2008).
40. Sudhir, P. R. et al. Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas. PLoS One 6, e20199 (2011).
41. Swingle, M., Ni, L. & Honkanen, R. E. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 365, 23-38 (2007).
42. Bialojan, C. & Takai, A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 256, 283-290 (1988).
43. Mumby, M. PP2A: unveiling a reluctant tumor suppressor. Cell 130, 21-24 (2007).
44. Omerovic, J., Hammond, D. E., Clague, M. J. & Prior, I. A. Ras isoform abundance and signalling in human cancer cell lines. Oncogene 27, 2754-2762 (2008).
45. Taus, T. et al. Universal and confident phosphorylation site localization using phosphoRS. J Proteome Res 10, 5354-5362 (2011).
46. Suni, V., Imanishi, S. Y., Maiolica, A., Aebersold, R. & Corthals, G. L. Confident Site Localization Using a Simulated Phosphopeptide Spectral Library. J Proteome Res 14, 2348-2359 (2015).
47. Sontag, E. et al. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 75, 887-897 (1993).
48. Andrabi, S., Gjoerup, O. V., Kean, J. A., Roberts, T. M. & Schaffhausen, B. Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc Natl Acad Sci USA 104, 19011-19016 (2007).
49. Chen, K. F. et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29, 6257-6266 (2010).
50. Zhou, X. W., Winblad, B., Guan, Z. & Pei, J. J. Interactions between glycogen synthase kinase 3beta, protein kinase B, and protein phosphatase 2A in tau phosphorylation in mouse N2a neuroblastoma cells. J Alzheimers Dis 17, 929-937 (2009).
51. Sears, R. et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14, 2501-2514 (2000).
52. Peterson, R. T., Desai, B. N., Hardwick, J. S. & Schreiber, S. L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA 96, 4438-4442 (1999).
53. Roux, P. P. et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates capdependent translation. J Biol Chem 282, 14056-14064 (2007).
54. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3, 11-22 (2003).
55. Horn, H. et al. KinomeXplorer: an integrated platform for kinome biology studies. Nat Methods 11, 603-604 (2014).
56. Xue, Y. et al. GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Mol Cell Proteomics 7, 1598-1608 (2008).
57. Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 40, D261-270 (2012).
58. Gougopoulou, D. M. et al. Mutations and expression of the ras family genes in leukemias. Stem Cells 14, 725-729 (1996).
59. Birkeland, E. et al. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer 107, 1997-2004 (2012).
60. Letourneux, C., Rocher, G. & Porteu, F. B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. Embo j 25, 727-738 (2006).
61. Braconi Quintaje, S. et al. Role of protein phosphatase 2A in the regulation of mitogen-activated protein kinase activity in ventricular cardiomyocytes. Biochem Biophys Res Commun 221, 539-547 (1996).
62. Lucas, C. M. et al. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117, 6660-6668 (2011).
63. Bockelman, C. et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 105, 989-995 (2011).
64. Li, W. et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 14, 3722-3728 (2008).
65. Niemela, M. et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its. Oncogene 31, 4266-4278 (2012).
66. Gaglio, D. et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 7, 523 (2011).
67. Kim, S., Lee, Y. Z., Kim, Y. S. & Bahk, Y. Y. A Proteomic approach for protein-profiling the oncogenic ras induced transformation (H-, K-, and N-Ras) in NIH/3T3 mouse embryonic fibroblasts. Proteomics 8, 3082-3093 (2008).
68. Young, T. et al. Proteomics Analysis of HRAS-Mediated Oncogenic Transformation in a Genetically Defined Human Ovarian Cancer Model. Oncogene 24, 6174-6184 (2005).
69. Jin, B. F. et al. Proteomics analysis reveals insight into the mechanism of H-Ras-mediated transformation. J Proteome Res 5, 2815-2823 (2006).
70. Blomster, H. A. et al. In vivo identification of sumoylation sites by a signature tag and cysteine-targeted affinity purification. J Biol Chem 285, 19324-19329 (2010).
71. Guzman, C., Bagga, M., Kaur, A., Westermarck, J. & Abankwa, D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One 9, e92444 (2014).
72. Cline, M. S. et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep 3, 2652 (2013).
73. Zhu, J. et al. The UCSC Cancer Genomics Browser. Nat Methods, 6 239-240 (2009).
74. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute. Bethesda, MD. (2014).
75. Vizcaino, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol 32, 223-226 (2014).